Cipla shares jump 4% on strong QoQ performance in June quarter; here’s what analysts said

At around 11:45 AM, the stock traded at ₹1,428 per equity share, up 2.51%.

The scrip has gained 1% in the past week but has fallen 1% over the month. On a year-to-date (YTD) basis, it has declined 5%.

While the share hit a 52-week high of ₹1,673 apiece on October 23, 2025, it touched a year’s low of ₹1,165.70 on April 2, 2026.

Cipla Q1 results

The pharmaceutical company recorded a consolidated net profit of ₹789 crore in the first quarter of FY26, reflecting a 42% quarter-on-quarter (QoQ) growth from ₹555 crore seen in the previous quarter of the last fiscal year (Q4 FY26), according to a regulatory filing dated July 23.

However, on a year-on-year (YoY) basis, the net profit has fallen 39% from ₹1,298 crore seen in the year-ago period.

It posted a 9% QoQ and 2% YoY jump in its total revenue from operations to ₹7,119 crore for the quarter under review, compared with ₹6,541 crore in Q4 FY26 and ₹6,957 crore in the year-ago period.

The pharma major’s EBITDA (earnings before interest, taxes, depreciation and amortisation) stood at ₹1,192 crore, marking a 25% QoQ increase from ₹955 crore in Q4 FY26. It declined 34% YoY from ₹1,778 crore in Q1 FY26.

The company’s EBITDA margin expanded by 214 basis points (bps) QoQ to 16.74% in contrast to 14.6%, while on a YoY basis it has contracted by 882 bps from 25.56%.

For Q1 FY27, Cipla maintained a strong net cash position of ₹9,494 crore and said that its debt largely comprises lease liabilities and working capital requirements.

The company reported R&D investments of ₹486 crore during the quarter, accounting for 6.8% of sales, marking a 12.3% year-on-year increase. This was driven by higher product filings and ongoing development initiatives.

What the CEO said

Commenting on the results, Achin Gupta, MD and Global CEO of Cipla, said: “We are pleased to share that we continue to make considerable progress across our focused markets. In Q1FY27, we delivered global revenues of ₹7,119 crore. Our One-India business grew at a solid 12% YoY.”

He added that the company’s branded prescription business delivered robust growth, with key therapies outpacing the market, trade generics recorded healthy growth, and anchor brands of Consumer Health Business maintained leadership position.

“The US business posted revenue of $162 million during the quarter. We expect continued sequential growth in North America, supported by the upcoming product pipeline. South Africa private business continued to grow faster than the market. Emerging Markets and Europe continued their growth trajectory with revenue growth of 5% YoY in USD terms on the back of a deep market focus strategy.”

Going ahead, Gupta added, the focus will be on growing the firm’s key markets, further building its flagship brands, investing in the future pipeline as well as focusing on resolutions on the regulatory front.

Analysts view

Furthermore, Cipla’s investment case remains anchored in the United States (US) launch pipeline and operating leverage it can unlock, with product approvals and Indore re-inspection outcome being the key-near term catalysts.

The analysts further stated that a strong 12% growth in the India market and improving visibility on key US launches reinforced their confidence in Cipla’s ability to deliver its FY27 margin guidance, with meaningful upside to earnings and margins in FY28 as the full benefit of the US pipeline materialises and geopolitical cost pressures ease.

The analysts added that the North America exit rate of $250 million in Q4 is a tall ask, especially with a gradual ramp-up of recently launched gVentolin.

EBITDA fell due to lower sales of cancer drug Revlimid, war-related costs, and pre-launch investments. However, it expects the US revenue run rate to improve from the second half og FY27 (H2).

Cipla has a total market capitalisation of ₹1.15 lakh crore as of July 24, 2026, according to data on the NSE.